Moreover, the results of our study revealed that MM patients who achieved a deep and long-lasting response to lenalidomide-based therapy had increased expression of the IL-17 receptor (IL-17R) compared to patients with newly diagnosed MM (NDMM) [10]. The gene discussed is IL17RA; the disease is Miyoshi myopathy.